P3171 - Exploring Comorbidities in Patients With Inflammatory Bowel Disease and Coexisting Irritable Bowel Syndrome: A National Inpatient Database Study

Ooreoluwa Fasola, MD¹, Godfrey Tabowei, MD², Gloria Erazo, MD³, Eunice Aregbesola, MD⁴, Anjul Verma, MD³, Eunice Omeludike, MD⁵, Guy Loic Nguefang Tchoukeu, MD³
1Texas Tech University Health Sciences Center - Permian Basin, Odessa, TX; 2Texas Tech University Health Science center, Permian Basin, Odessa, TX; 3Texas Tech University Health Sciences Center, Odessa, TX; 4University of Missouri , Columbia, Columbia, MO; 5Piedmont Athens Regional Medical Centre, Athens, GA

Introduction: Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are two common chronic gastrointestinal disorders which can coexist in certain patients. Comorbidities have been identified in patients with IBD but little is known about comorbidities in patients with IBD and coexisting IBS. This study aims to compare comorbidities in patients with IBD and coexisting IBS (IBDIBS) versus those without coexisting IBS (IBDnoIBS).

Methods: A retrospective analysis of patients admitted with a diagnosis of IBD was conducted using the National Inpatient Sample (NIS) 2020. ICD-10 codes were used to identify individuals with IBD which was further divided into two groups based on the presence or absence of a history of IBS. The risks of cardiovascular and metabolic comorbidities were compared between the two groups.

Results: There were 308,690 patients admitted with IBD and 275 (0.09%) had coexisting IBS. There were more females in the IBDIBS group compared to the IBDnoIBS group (76.3% vs 55.3%). Mean age of presentation is relatively the same in the IBDIBS vs IBDnoIBS (50.9 vs 53.7) respectively. Majority of the population were non-Hispanic whites in IBDIBS (81.4%) and IBDnoIBS (78.0%). After adjusting for confounders, the IBDIBS group experienced a statistically significant increase in the length of hospital stay by 1.7 days (P = 0.048, 95% CI 0.17–3.49). Total hospital charges were $59,719 for IBDIBS patients compared to $67,359 for the IBDnoIBS group, with no significant difference observed after adjusting for confounders (P > 0.05). Comparing both groups, there was a significant increase in the odds of dyslipidemia (aOR 2.66, 95% CI 1.38–5.10, P = 0.03) and hypothyroidism (aOR 6.75, 95% CI 1.55–29.3, P = 0.01) in the IBDIBS group. While the odds of hypertension, obesity, coronary artery disease, and heart failure were higher in the IBDIBS group compared to the IBDnoIBS group, these findings were not statistically significant (P > 0.05).

Discussion: This study showed hospitalized patients with coexisting IBD and IBS were more likely to be female, have longer hospital stays than IBS alone. They also had higher likelihood of having dyslipidemia and hypothyroidism. These findings highlight the added clinical burden associated with coexisting IBS in patients with IBD.

Disclosures:
Ooreoluwa Fasola indicated no relevant financial relationships.
Godfrey Tabowei indicated no relevant financial relationships.
Gloria Erazo indicated no relevant financial relationships.
Eunice Aregbesola indicated no relevant financial relationships.
Anjul Verma indicated no relevant financial relationships.
Eunice Omeludike indicated no relevant financial relationships.
Guy Loic Nguefang Tchoukeu indicated no relevant financial relationships.

Ooreoluwa Fasola, MD¹, Godfrey Tabowei, MD², Gloria Erazo, MD³, Eunice Aregbesola, MD⁴, Anjul Verma, MD³, Eunice Omeludike, MD⁵, Guy Loic Nguefang Tchoukeu, MD³. P3171 - Exploring Comorbidities in Patients With Inflammatory Bowel Disease and Coexisting Irritable Bowel Syndrome: A National Inpatient Database Study, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.